Analytical performance of reagent for assaying tau protein in human plasma and feasibility study screening neurodegenerative diseases

Immunomagnetic reduction (IMR), which involves the use of antibody-functionalized magnetic nanoparticles to specifically label target biomarkers, was utilized to develop an assay for total tau protein in human plasma. The analytic properties of the IMR assay on tau protein were investigated. The lim...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2017-08, Vol.7 (1), p.9304-12, Article 9304
Main Authors: Yang, Shieh-Yueh, Chiu, Ming-Jang, Chen, Ta-Fu, Lin, Chin-Hsien, Jeng, Jiann-Shing, Tang, Sung-Chun, Lee, Yen-Fu, Yang, Che-Chuan, Liu, Bing-Hsien, Chen, Hsin-Hsien, Wu, Chau-Chung
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Alzheimer's disease
Cognitive ability
Dementia
Dementia disorders
Diagnostic Tests, Routine - methods
Feasibility Studies
Frontotemporal dementia
Humans
Mass Screening - methods
Middle Aged
Movement disorders
Nanoparticles
Neurodegenerative diseases
Neurodegenerative Diseases - diagnosis
Parkinson's disease
Plasma
Plasma - chemistry
Proteins
ROC Curve
Sensitivity and Specificity
Sexually transmitted diseases
STD
Tau protein
tau Proteins - blood
Vascular dementia
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immunomagnetic reduction (IMR), which involves the use of antibody-functionalized magnetic nanoparticles to specifically label target biomarkers, was utilized to develop an assay for total tau protein in human plasma. The analytic properties of the IMR assay on tau protein were investigated. The limit of detection was found to be 0.026 pg/ml. Other properties such as Hook effect, assay linearity, dilution recovery range, reagent stability, interference test, and spiked recovery were also characterized. The ultra-sensitive IMR assay was applied to detect the plasma tau protein levels of subjects with prevalent neurodegenerative diseases, such as Alzheimer's disease (AD), mild cognitive impairment (MCI) due to AD, Parkinson's disease (PD), frontotemporal dementia (FTD) and vascular dementia (VD). The concentrations of plasma tau protein in patients with VD, PD, MCI due to AD, FTD, and AD patients were higher than that of healthy controls. Using an ROC curve analysis, the cutoff value for discriminating dementia patients from healthy controls was 17.43 pg/ml, resulting in 0.856 and 0.727 for clinical sensitivity and specificity, respectively. The area under the ROC curve was 0.908. These results imply that the IMR plasma tau assay would be useful to screen for prevalent neurodegenerative diseases.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-017-09009-3